NASDAQ · EWTX
Edgewise Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for EWTX: Nov 5, 2026
Edgewise Therapeutics, Inc. Common Stock is estimated to report earnings on 11/05/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 6 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.55. The reported EPS for the same quarter last year was $-0.39.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.55 | $-0.52 | $-0.61 | 6 |
| Dec 2026 | $-0.52 | $-0.42 | $-0.65 | 8 |
| Mar 2027 | $-0.50 | $-0.40 | $-0.56 | 5 |
| Jun 2027 | $-0.52 | $-0.41 | $-0.59 | 5 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · RTTNews- Zacks · Oct 19, 8:40 AM EDTCan Myqorzo's Expansion and Growing Adoption Drive CYTK's Growth?Cytokinetics' Myqorzo gains commercial traction with growing prescriptions, international launches and promising clinical data that could expand its market opportunity.
- RTTNews · Oct 8, 2:02 PM EDTEdgewise Therapeutics Doses First Patient In Phase 2 HFpEF Trial; Stock Down(RTTNews) – Edgewise Therapeutics (EWTX) announced that the first patient has been dosed in the Phase 2 EQUINOX-HFpEF trial evaluating EDG-15400 in adults with symptomatic heart failure with preserved ejection fraction (HFpEF) and a left ventricular ejection fraction of at least
- Zacks · Oct 2, 8:15 AM EDTWill Camzyos Growth Keep Driving BMY's Cardiovascular Portfolio?Bristol Myers' Camzyos gains a broader FDA label and strong sales growth, while emerging competitors and pipeline setbacks shape its cardiovascular outlook.
- Zacks · Sep 4, 3:36 PM EDTWill Camzyos' Long-Term Benefits Strengthen BMY's Growth Outlook?Bristol Myers??? Camzyos delivers durable five-year benefits, rising sales and potential adolescent label expansion.
- Zacks · Sep 2, 2:30 PM EDTCan CYTK's Aficamten Strengthen Its HCM Growth Prospects?Cytokinetics' aficamten shows added benefits in HCM studies, strengthening its potential in non-obstructive and obstructive disease.
- Zacks · Aug 27, 10:32 AM EDTCan Camzyos' Growth Offset Bristol Myers' Patent Pressures?BMY's Camzyos gains momentum as an adolescent expansion nears an FDA decision, while rivals advance competing heart drugs.
- Zacks · Jul 17, 10:42 AM EDTViking Therapeutics to Report Q2 Earnings: What's in Store for the Stock?VKTX's Q2 report could hinge on VK2735 pipeline updates as investors await progress on obesity studies and maintenance dosing plans.
- Zacks · Jul 10, 2:10 PM EDTWill Myqorzo Drive Cytokinetics Higher Despite Competitive Pressure?CYTK enters a new era after Myqorzos FDA approval, with early US uptake, European expansion and lifecycle studies fueling its commercial momentum.
- RTTNews · Jun 16, 7:53 AM EDTEdgewise Therapeutics Shares Fall Pre-Market After Phase 2 HCM Update(RTTNews) – Edgewise Therapeutics, Inc. (EWTX) reported encouraging top-line results from its 12-week Phase 2 Part D CIRRUS-HCM trial evaluating EDG-7500 in patients with obstructive and nonobstructive hypertrophic cardiomyopathy, showing meaningful improvements in heart function
- Zacks · Jun 2, 11:13 AM EDTEdgewise Therapeutics Stock Hits Record High on $2.65B Servier DealEWTX surges 18% to a record high after striking a $2.65 billion neuromuscular business divestiture deal with Servier, sharpening focus on its cardiovascular pipeline.
- RTTNews · Jun 1, 9:08 AM EDTEdgewise Therapeutics To Sell Muscular Dystrophy Business & Sevasemten For Up To $2.65 Bln(RTTNews) – Edgewise Therapeutics, Inc. (EWTX), a biopharmaceutical company, Monday announced that it has agreed to sell its muscular dystrophy business and Sevasemten to Servier, an independent pharmaceutical group, for $1.55 billion in cash and up to $1.1 billion in additional
- Zacks · Apr 17, 1:37 PM EDTCan Myqorzo Drive Growth for Cytokinetics Amid Competition?CYTK enters the commercial stage with FDA-approved Myqorzo for oHCM, eyeing strong market share, but faces stiff competition and execution risks.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Edgewise Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.